



Mahwah, NJ – April 1, 2026 – Lifestar Pharma LLC, a U.S. subsidiary of Mankind Pharma Limited, today announced the launch of **Bimatoprost Ophthalmic Solution 0.01%**, the first generic equivalent to LUMIGAN® (Bimatoprost ophthalmic solution 0.01%)

This milestone emphasizes the company’s continued commitment to expanding access to high-quality, affordable medications for patients across the United States. As the first generic entrant, Lifestar is uniquely positioned to deliver meaningful cost savings while maintaining the highest standards of quality and supply reliability.

“We are excited to launch first generic version of Bimatoprost Ophthalmic Solution 0.01% in 2.5 mL, 5 mL, and 7.5 mL presentations, and proud to provide a cost-effective alternative while ensuring continuity of supply for our partners.” stated David Gann, SVP of Commercialization at Lifestar Pharma.

Dr. Vijay Soni, CEO of Lifestar, added: “Bringing Bimatoprost Ophthalmic Solution 0.01% to market underscores our mission to improve patient access to essential therapies. We are seeing continued momentum in expanding our sterile products portfolio.”

Bimatoprost Ophthalmic Solution 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension—conditions affecting millions of Americans. According to IQVIA®, U.S. annual sales for this product reached approximately \$681 million for the 12 months ending January 2026.

Lifestar Pharma has built a strong reputation for dependable supply, operational excellence, and customer-focused partnerships. This launch further strengthens the company’s ophthalmics portfolio and reinforces its role as a trusted partner to wholesalers, GPOs, and healthcare providers nationwide.

The product is now available for ordering through Lifestar Pharma’s distribution network.

About Lifestar Pharma LLC

Lifestar Pharma LLC, a Mankind Group Company, is a U.S.-based pharmaceutical company dedicated to delivering high-quality, affordable generic medications. With a focus on reliability, efficiency, and strong customer partnerships, Lifestar Pharma continues to expand its portfolio across multiple therapeutic categories to better serve patients and healthcare providers. The Company has a diverse portfolio of over 55 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables, ophthalmic and inhalation dosages.